10-Q quarterly report · filed Oct 7, 2026

NEOGEN CORP (NEOG) Q3 2026 10-Q Quarterly Report

Short answer

NEOGEN CORP (NEOG) filed its Q3 2026 10-Q quarterly report on Oct 7, 2026 for the quarter ended Aug 31, 2026. Quarterly revenue was $223M (up 6.5% year over year) with net income of −$12M.

Q3 2026 key financials · XBRL

Revenue
$223M
+6.5% YoY
Net income
−$12M
−132.7% YoY
Operating margin
-0.8%
Gross margin
47.4%
EPS (diluted)
−$0.05
−129.4% YoY

Source: XBRL data from the NEOGEN CORP (NEOG) Q3 2026 10-Q on SEC EDGAR. USD.

NEOGEN CORP Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $222.8M, up $13.6M or 6.5% YoY
  • Gross margin 47.4% vs 45.4% YoY, operating loss $(1.8)M vs $(16.1)M
  • Food Safety strongest segment: revenue $163.2M, up 7.3%; Animal Safety revenue $59.6M, up 4.4%
  • Cash $172.0M; operating cash flow $12.9M vs $10.8M, with $20.0M term-loan prepayment
  • Headwinds: inflation, tariffs, elevated interest rates, geopolitical tensions; Genomics divestiture reviews expected through December 2026

Risk Factors

  • Genomics divestiture risk: ACCC and NZCC moved reviews to phase two, potentially delaying the $160.0 million Zoetis transaction
  • Product compliance risk: FDA Warning Letter followed contamination findings involving recalled Vet HyCoat units
  • Litigation risk: securities class-action dismissal appealed on September 8, 2026, leaving appeal exposure unresolved
  • Operational risk: Petrifilm internal manufacturing preparation creating duplicative costs and production inefficiencies
  • Debt liquidity risk: $774.2 million net debt outstanding, with $199.9 million revolving borrowing capacity available

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other NEOGEN CORP quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.